| Ronak Jagdeep Shah, | |
|
5325 Faraon St, Saint Joseph, MO 64506-3488 | |
| (816) 271-6406 | |
| (816) 271-7986 |
| Full Name | Ronak Jagdeep Shah |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Location | 5325 Faraon St, Saint Joseph, Missouri |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871150136 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 2022025517 (Missouri) | Primary |
| 207R00000X | Internal Medicine | 2022025517 (Missouri) | Secondary |
| Entity Name | Heartland Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477575405 PECOS PAC ID: 6709772767 Enrollment ID: O20040225001201 |
News Archive
Columbia Engineering researchers report that Sofosbuvir-terminated RNA is more resistant to the proofreader of SARS-CoV-2, the virus that causes COVID-19, than Remdesivir-terminated RNA.
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.
About one in 8,000 people have facioscapulohumeral muscular dystrophy, according to a 2014 study, which is relatively common in the world of genetic diseases.
A team of researchers from the University of Houston and the University of Pennsylvania are working to bring a new biosensor for detecting the recurrence of prostate cancer to the doctor's office.
› Verified 4 days ago
| Entity Name | Mosaic Medical Center - Maryville |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184189797 PECOS PAC ID: 3678813896 Enrollment ID: O20190405001537 |
News Archive
Columbia Engineering researchers report that Sofosbuvir-terminated RNA is more resistant to the proofreader of SARS-CoV-2, the virus that causes COVID-19, than Remdesivir-terminated RNA.
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.
About one in 8,000 people have facioscapulohumeral muscular dystrophy, according to a 2014 study, which is relatively common in the world of genetic diseases.
A team of researchers from the University of Houston and the University of Pennsylvania are working to bring a new biosensor for detecting the recurrence of prostate cancer to the doctor's office.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ronak Jagdeep Shah, 5301 Faraon St Ste 120, Saint Joseph, MO 64506-3512 Ph: (816) 271-1066 | Ronak Jagdeep Shah, 5325 Faraon St, Saint Joseph, MO 64506-3488 Ph: (816) 271-6406 |
News Archive
Columbia Engineering researchers report that Sofosbuvir-terminated RNA is more resistant to the proofreader of SARS-CoV-2, the virus that causes COVID-19, than Remdesivir-terminated RNA.
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.
About one in 8,000 people have facioscapulohumeral muscular dystrophy, according to a 2014 study, which is relatively common in the world of genetic diseases.
A team of researchers from the University of Houston and the University of Pennsylvania are working to bring a new biosensor for detecting the recurrence of prostate cancer to the doctor's office.
› Verified 4 days ago
Dr. Tamara Louise Crouse, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5325 Faraon St, Saint Joseph, MO 64506 Phone: 816-271-6406 Fax: 816-271-7986 | |
Dr. Steffan Anthony Libarnes, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5325 Faraon St, Saint Joseph, MO 64506 Phone: 816-271-6406 Fax: 816-271-7986 | |
Dr. Kyle M. Mcwhirter, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5325 Faraon St, Saint Joseph, MO 64506 Phone: 816-271-6406 Fax: 816-271-7986 | |
Isaac Daniel Demke, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 5325 Faraon St, Saint Joseph, MO 64506 Phone: 816-271-7506 Fax: 816-271-7912 | |
Allison Marie Voeks Roe, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5325 Faraon St, Saint Joseph, MO 64506 Phone: 816-271-6406 | |
Aadil Saeed Ahmed, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5325 Faraon St, Saint Joseph, MO 64506 Phone: 816-271-6000 | |
Sai Siva Ram Guduru, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5325 Faraon St, Saint Joseph, MO 64506 Phone: 816-271-6406 Fax: 816-271-7986 |